Tongji Hospital is recruiting 15 participants for a single-center, dose-escalation Phase 1 study primarily assessing adverse events through 48 weeks after treatment.
The Phase 2 study will enroll about 53 patients to evaluate a single off-the-shelf CAR T-cell dose, with complete renal response at Week 26 as the primary endpoint.
Mesoblast has secured exclusive global rights to a CAR technology platform to engineer its MSC therapies for more precise targeting and greater potency in inflammatory and autoimmune diseases, including bowel disease and lupus nephritis.
Gallant is betting the future of veterinary regenerative medicine lies in scalable, well-characterized cell therapies. By sourcing mesenchymal stem cells from uterine tissue collected during routine spays, it has built an off-the-shelf platform with consistent, high-yield cells and FDA-aligned manufacturing, with a potential first FDA…
The new grants will support diverse early-stage research projects, aiming to advance regenerative medicine tools and future therapies.